Literature DB >> 19148677

Clinical practice: pulmonary hypertension in children.

Daniel De Wolf1.   

Abstract

INTRODUCTION: Pulmonary arterial hypertension is a rare disorder in childhood, the two most common types being idiopathic pulmonary arterial hypertension and pulmonary hypertension associated with congenital left-to-right shunt lesions, together accounting for almost 90% of cases. DISCUSSION: The clinical presentation of idiopathic pulmonary arterial hypertension (familial and non familial) is essentially non-specific and varies with age. Pulmonary vasoreactivity testing identifies responders and non-responders. Responders are treated with calcium channel blockers and have a better prognosis. Non-responders have a very limited survival beyond diagnosis if not treated with more selective pulmonary arterial vasodilators. Prostacyclin, endothelin receptor antagonists and phosphodiesterase-5 inhibitors improve haemodynamics, functional class and exercise tolerance and delay deterioration. Patients with congenital left-to-right shunts and irreversible pulmonary arterial hypertension leading to Eisenmenger's syndrome have multiple organ disease. Despite a very pronounced exercise intolerance, their clinical course is rather stable with survival up to 40-60 years, depending on the complexity of their underlying cardiac defect. Treatment is based on general measures along with the same three types of selective pulmonary vasodilators as in idiopathic pulmonary arterial disease. Improvement in haemodynamics, functional class and exercise tolerance are comparable for both patient groups.
CONCLUSION: Pulmonary hypertension in children is idiopathic or associated with congenital heart disease in the majority of patients. Treatment with new selective pulmonary vasodilators offers haemodynamic and functional improvement.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148677     DOI: 10.1007/s00431-008-0920-x

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  33 in total

Review 1.  Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric heart transplantation report--2007.

Authors:  Mark M Boucek; Paul Aurora; Leah B Edwards; David O Taylor; Elbert P Trulock; Jason Christie; Fabienne Dobbels; Axel O Rahmel; Berkeley M Keck; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2007-08       Impact factor: 10.247

2.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  Effects of long-term bosentan in children with pulmonary arterial hypertension.

Authors:  Erika Berman Rosenzweig; D Dunbar Ivy; Allison Widlitz; Aimee Doran; Lori R Claussen; Delphine Yung; Steven H Abman; Adele Morganti; Ngoc Nguyen; Robyn J Barst
Journal:  J Am Coll Cardiol       Date:  2005-08-16       Impact factor: 24.094

4.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension.

Authors:  Ronald J Raymond; Alan L Hinderliter; Park W Willis; David Ralph; Edgar J Caldwell; William Williams; Neil A Ettinger; Nicholas S Hill; Warren R Summer; Bennett de Boisblanc; Todd Schwartz; Gary Koch; Linda M Clayton; Maria M Jöbsis; James W Crow; Walker Long
Journal:  J Am Coll Cardiol       Date:  2002-04-03       Impact factor: 24.094

5.  Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.

Authors:  S C Mathai; R E Girgis; M R Fisher; H C Champion; T Housten-Harris; A Zaiman; P M Hassoun
Journal:  Eur Respir J       Date:  2006-11-01       Impact factor: 16.671

6.  Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension.

Authors:  Joseph K Perloff; Eric M Hart; S Melanie Greaves; Pamela D Miner; John S Child
Journal:  Am J Cardiol       Date:  2003-07-15       Impact factor: 2.778

7.  BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.

Authors:  K E Roberts; J J McElroy; W P K Wong; E Yen; A Widlitz; R J Barst; J A Knowles; J H Morse
Journal:  Eur Respir J       Date:  2004-09       Impact factor: 16.671

8.  Outcomes in children with idiopathic pulmonary arterial hypertension.

Authors:  Delphine Yung; Allison C Widlitz; Erika Berman Rosenzweig; Diane Kerstein; Greg Maislin; Robyn J Barst
Journal:  Circulation       Date:  2004-08-02       Impact factor: 29.690

9.  Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program.

Authors:  Maurice Beghetti; Marius M Hoeper; David G Kiely; Joern Carlsen; Barbara Schwierin; Eleanor S Segal; Marc Humbert
Journal:  Pediatr Res       Date:  2008-08       Impact factor: 3.756

10.  Primary pulmonary hypertension. A national prospective study.

Authors:  S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

View more
  5 in total

1.  Dispersion durations of P-wave and QT interval in children with congenital heart disease and pulmonary arterial hypertension.

Authors:  Fatih Sap; Zehra Karataş; Hakan Altin; Hayrullah Alp; Bülent Oran; Tamer Baysal; Sevim Karaarslan
Journal:  Pediatr Cardiol       Date:  2012-09-13       Impact factor: 1.655

2.  A Retrospective Review of Infants Receiving Sildenafil.

Authors:  Aliva De; Payal Shah; Jacqueline Szmuszkovicz; Shazia Bhombal; Stanley Azen; Roberta M Kato
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

Review 3.  Clinical practice. The impact of lung disease on the heart and cardiac disease on the lungs.

Authors:  Fiona Healy; Brian D Hanna; Raezelle Zinman
Journal:  Eur J Pediatr       Date:  2009-07-29       Impact factor: 3.183

4.  Left-to-Right Shunt with Congenital Heart Disease: Single Center Experience.

Authors:  Ayhan Cevik; Rana Olgunturk; Serdar Kula; Berna Saylan; Ayhan Pektas; Deniz Oguz; Sedef Tunaoglu
Journal:  ISRN Cardiol       Date:  2013-06-23

Review 5.  Biomarkers for pediatric pulmonary arterial hypertension - a call to collaborate.

Authors:  Kelley L Colvin; Melanie J Dufva; Ryan P Delaney; D Dunbar Ivy; Kurt R Stenmark; Michael E Yeager
Journal:  Front Pediatr       Date:  2014-02-03       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.